Rivaroxaban Hypericum Trial

Phase 1 Completed 12 enrolled Insel Gruppe AG, University Hospital Bern Bayer · collab

Non-randomizedSequentialOpen-labelOther

Summary

Single-center, open-label, sequential treatment study to investigate the influence of the combined P-glycoprotein and CYP3A4 inducer hypericum perforatum on the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy volunteers.

Timeline

Start: 2019-02-13
Primary completion: 2019-04-09
Completion: 2019-04-09

Publications

Results Scholz I, Liakoni E, Hammann F, Grafinger KE, Duthaler U, Nagler M, Krahenbuhl S, Haschke M. Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. Br J Clin Pharmacol. 2021 Mar;87(3):1466-1474. doi: 10.1111/bcp.14553. Epub 2020 Oct 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivaroxaban	Other / unclassified	20 mg	Oral
Subject	St Johns Wort Extract	Unknown	450 mg	Oral

Indications

No indication recorded.